Market Research Logo

Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Medical Devices Pipeline Assessment, 2016

Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Medical Devices Pipeline Assessment, 2016

Summary

GlobalData's Medical Devices sector report, “Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Medical Devices Pipeline Assessment, 2016 provides an overview of Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) Overview
3 Products under Development
3.1 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development
3.2 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Territory
3.3 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path
3.4 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date
3.5 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Ongoing Clinical Trials
4 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products under Development by Companies
4.1 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) Companies - Pipeline Products by Stage of Development
4.2 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development
5 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) Companies and Product Overview
5.1 AnGes MG, Inc. Company Overview
5.1.1 AnGes MG, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.2 AngioCure, Inc. Company Overview
5.2.1 AngioCure, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.3 AVIDAL Vascular GmbH Company Overview
5.3.1 AVIDAL Vascular GmbH Pipeline Products & Ongoing Clinical Trials Overview
5.4 Bayer HealthCare AG Company Overview
5.4.1 Bayer HealthCare AG Pipeline Products & Ongoing Clinical Trials Overview
5.5 Contego Medical, LLC Company Overview
5.5.1 Contego Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview
5.6 Elixir Medical Corporation Company Overview
5.6.1 Elixir Medical Corporation Pipeline Products & Ongoing Clinical Trials Overview
5.7 eucatech AG Company Overview
5.7.1 eucatech AG Pipeline Products & Ongoing Clinical Trials Overview
5.8 Lifetech Scientific (Shenzhen) Co., Ltd. Company Overview
5.8.1 Lifetech Scientific (Shenzhen) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
5.9 Medtronic plc Company Overview
5.9.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview
5.10 Micell Technologies, Inc. Company Overview
5.10.1 Micell Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.11 Nipro Corporation Company Overview
5.11.1 Nipro Corporation Pipeline Products & Ongoing Clinical Trials Overview
5.12 NuVascular Technologies Inc Company Overview
5.12.1 NuVascular Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
5.13 QT Vascular Ltd. Company Overview
5.13.1 QT Vascular Ltd. Pipeline Products & Ongoing Clinical Trials Overview
5.14 QualiMed Innovative Medizinprodukte GmbH Company Overview
5.14.1 QualiMed Innovative Medizinprodukte GmbH Pipeline Products & Ongoing Clinical Trials Overview
5.15 Rontis AG Company Overview
5.15.1 Rontis AG Pipeline Products & Ongoing Clinical Trials Overview
5.16 SiL Vascular Ltd Company Overview
5.16.1 SiL Vascular Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.17 SurModics, Inc. Company Overview
5.17.1 SurModics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.18 Terumo Corporation Company Overview
5.18.1 Terumo Corporation Pipeline Products & Ongoing Clinical Trials Overview
5.19 The Spectranetics Corporation Company Overview
5.19.1 The Spectranetics Corporation Pipeline Products & Ongoing Clinical Trials Overview
5.20 Vascular Nanotransfer Technologies Company Overview
5.20.1 Vascular Nanotransfer Technologies Pipeline Products & Ongoing Clinical Trials Overview
6 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Recent Developments
6.1 Jul 21, 2016: Federal Circuit Court Rules in Appeal
6.2 Jul 20, 2016: 12-month Results of the ILLUMENATE European Randomized Clinical Trial to be Presented at the Amputation Prevention Symposium
6.3 Jul 15, 2016: Daiichi Sankyo to Raise USD713.4 Million in Public Offering of 0.81% 5th Series Bonds Due 2036
6.4 Jul 15, 2016: Daiichi Sankyo to Raise USD237.8 Million in Public Offering of 1.2% 6th Series Bonds Due 2046
6.5 Jul 13, 2016: Medtronic Receives FDA Approval for IN.PACT Admiral DCB 150 mm Lengths
6.6 Jul 13, 2016: Boston Scientific Elects Yoshiaki Fujimori to Board of Directors
6.7 Jun 30, 2016: FTSE Russell Selects Daiichi Sankyo for FTSE4Good Global Index
6.8 Jun 30, 2016: NuVasive Agrees to Settle Patent Litigation With Medtronic
6.9 Jun 08, 2016: Boston Scientific Announces Restructuring Program to Support Long-Term Growth and Innovation
6.10 Jun 06, 2016: Medtronic Outlines Future Growth Vision at Investor Day
6.11 Jun 01, 2016: Second Interim Analysis on ILLUMENATE Global Study Presented on Spectranetics’ Stellarex drug-coated balloon at NCVH
6.12 May 31, 2016: Medtronic Reports Fourth Quarter and Fiscal Year 2016 Financial Results
6.13 May 16, 2016: iVascular Receives CE Mark Approval for LUMINOR 18 Drug Eluting Balloon
6.14 May 12, 2016: Daiichi Sankyo Announces Changes to Representative Director and Members of the Board
6.15 May 06, 2016: The outcome of arbitration proceeding with certain former shareholders of Ranbaxy
6.16 Apr 26, 2016: 12-Month Interim ILLUMENATE Global Study Data Presented on Spectranetics’ Stellarex drug-coated balloon at Charing Cross
6.17 Apr 26, 2016: Medtronic IN.PACT Admiral DCB Maintains Durable, Consistent and Safe Outcomes in Challenging Peripheral Cases
6.18 Apr 25, 2016: QT Vascular Submits IDE Requesting Permission to Begin Pivotal Trial of Its Drug-Coated Chocolate Balloon in The United States
6.19 Apr 06, 2016: SurModics Announces First Patient Enrolled in IDE Study of SurVeil Drug-Coated Balloon
6.20 Feb 10, 2016: QT Vascular Announces Another Positive Outcome in Litigation with Spectranetics/Angioscore
6.21 Jan 26, 2016: BIOTRONIK Announces Expansion Of Passeo-18 Lux Drug-Coated Balloon Portfolio
6.22 Jan 11, 2016: Medtronic IN.PACT Admiral DEB Receives CE Mark For Treatment Of AV Access In Patients With End-Stage Renal Disease
6.23 Dec 14, 2015: Medtronic Announces New High-Tech Facility in Galway; Building on Global Synergies
6.24 Nov 26, 2015: Update On AngioScore Litigation - QT Vascular Ltd
6.25 Nov 20, 2015: BIOTRONIK Announces Improved Patient Outcomes with Innovative “Combination Therapy” for Peripheral Artery Disease
6.26 Nov 02, 2015: IN.PACT Admiral Drug-Coated Balloon Cost-Effectiveness Study and Global Study Results of In-Stent Restenosis Population Highlighted in Late Breaking Clinical Trials at VIVA 2015
6.27 Nov 02, 2015: Medtronic Begins REALITY Study To Assess IN.PACT Admiral DCB In Patients With PAD
6.28 Oct 14, 2015: Medtronic Drug-Coated Balloon Sustains Superiority Over Balloon Angioplasty at Two Years in Patients with Peripheral Arterial Disease
6.29 Oct 05, 2015: SurModics Receives FDA IDE Approval for Early Feasibility Study of the SurVeil Drug-Coated Balloon
6.30 Oct 05, 2015: QT Vascular Announces Interim Clinical Trial Results Of Chocolate Touch
6.31 Oct 05, 2015: SurModics Receives FDA IDE Approval for Early Feasibility Study of the SurVeil Drug-Coated Balloon
6.32 Sep 15, 2015: New Technique at Morris Hospital Improves Treatment of Peripheral Artery Disease
6.33 Sep 07, 2015: QT Vascular Announces CE Mark Clearance Of Chocolate Touch By LRQA 0088
6.34 Aug 03, 2015: CMS Grants New Technology Add-On Payment for Inpatient Use of Medtronic's Drug-Coated Balloon
6.35 Jul 29, 2015: Spectranetics Completes Enrollment in ILLUMENATE Pivotal Study to Assess Safety and Efficacy of Stellarex Drug-Coated Balloon Technology
7 Appendix
7.1 Methodology
7.2 About GlobalData
7.3 Contact Us
7.4 Disclaimer
1.1 List of Tables
Table 1: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development
Table 2: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Territory
Table 3: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path
Table 4: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date
Table 5: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Ongoing Clinical Trials
Table 6: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) Companies - Pipeline Products by Stage of Development
Table 7: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development
Table 8: AnGes MG, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 9: Collategene Drug-Eluting Balloon Catheter - Product Status
Table 10: Collategene Drug-Eluting Balloon Catheter - Product Description
Table 11: NF-kB Decoy Oligo Coated PTA Balloon Catheter - Product Status
Table 12: NF-kB Decoy Oligo Coated PTA Balloon Catheter - Product Description
Table 13: AngioCure, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 14: AngioCure TOP-C Smart Balloon Catheter - Product Status
Table 15: AngioCure TOP-C Smart Balloon Catheter - Product Description
Table 16: AVIDAL Vascular GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 17: WOMBAT - Peripheral Version - Product Status
Table 18: WOMBAT - Peripheral Version - Product Description
Table 19: Bayer HealthCare AG Pipeline Products & Ongoing Clinical Trials Overview
Table 20: Cotavance Paclitaxel Coated Balloon Angioplasty Catheter - Product Status
Table 21: Cotavance Paclitaxel Coated Balloon Angioplasty Catheter - Product Description
Table 22: Contego Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 23: Tibial Artery Drug Eluting Balloon - Product Status
Table 24: Tibial Artery Drug Eluting Balloon - Product Description
Table 25: Elixir Medical Corporation Pipeline Products & Ongoing Clinical Trials Overview
Table 26: Peripheral Vascular Resorbable Scaffold - Product Status
Table 27: Peripheral Vascular Resorbable Scaffold - Product Description
Table 28: eucatech AG Pipeline Products & Ongoing Clinical Trials Overview
Table 29: Support - Product Status
Table 30: Support - Product Description
Table 31: Lifetech Scientific (Shenzhen) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
Table 32: PTA Drug Eluting Balloon - Product Status
Table 33: PTA Drug Eluting Balloon - Product Description
Table 34: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview
Table 35: DCB BTK - Product Status
Table 36: DCB BTK - Product Description
Table 37: Micell Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 38: Drug-Coated Balloon - Product Status
Table 39: Drug-Coated Balloon - Product Description
Table 40: Nipro Corporation Pipeline Products & Ongoing Clinical Trials Overview
Table 41: Peripheral Drug-Eluting Balloon - Product Status
Table 42: Peripheral Drug-Eluting Balloon - Product Description
Table 43: NuVascular Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 44: NuSpun DE Balloon - Product Status
Table 45: NuSpun DE Balloon - Product Description
Table 46: QT Vascular Ltd. Pipeline Products & Ongoing Clinical Trials Overview
Table 47: Chocolate Touch PTA Drug Coated Balloon - Product Status
Table 48: Chocolate Touch PTA Drug Coated Balloon - Product Description
Table 49: Silk PTA Balloon Catheter - Product Status
Table 50: Silk PTA Balloon Catheter - Product Description
Table 51: QT Vascular Ltd. - Ongoing Clinical Trials Overview
Table 52: Chocolate Touch PTA Drug Coated Balloon - First in Human Evaluation of the Drug-coated Chocolate Balloon for Percutaneous Transluminal Revascularization of Infrainguinal Arterial Disease
Table 53: Chocolate Touch PTA Drug Coated Balloon - Pivotal Trial of Drug-coated Chocolate Balloon in The United States
Table 54: QualiMed Innovative Medizinprodukte GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 55: Kinesyx-Based Peripheral Drug Coated Balloon - Product Status
Table 56: Kinesyx-Based Peripheral Drug Coated Balloon - Product Description
Table 57: Rontis AG Pipeline Products & Ongoing Clinical Trials Overview
Table 58: Drug Eluting Dilatation Catheter - Product Status
Table 59: Drug Eluting Dilatation Catheter - Product Description
Table 60: SiL Vascular Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 61: Peripheral Vascular Balloon - Product Status
Table 62: Peripheral Vascular Balloon - Product Description
Table 63: SurModics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 64: SurVeil Drug Coated Balloon - Arterio Venous (AV) Fistulas - Product Status
Table 65: SurVeil Drug Coated Balloon - Arterio Venous (AV) Fistulas - Product Description
Table 66: SurVeil Drug Coated Balloon - Below The Knee (BTK) - Product Status
Table 67: SurVeil Drug Coated Balloon - Below The Knee (BTK) - Product Description
Table 68: SurVeil Drug Coated Balloon - SFA - Product Status
Table 69: SurVeil Drug Coated Balloon - SFA - Product Description
Table 70: SurModics, Inc. - Ongoing Clinical Trials Overview
Table 71: SurVeil Drug Coated Balloon - SFA - A Prospective, Multi-center, Single-arm Trial to Assess the Safety and Feasibility of the SurModics Drug Coated Balloon in the Treatment of Subjects with De Novo Lesions of the Femoropopliteal Artery
Table 72: Terumo Corporation Pipeline Products & Ongoing Clinical Trials Overview
Table 73: Drug Coated Balloon Catheter - Product Status
Table 74: Drug Coated Balloon Catheter - Product Description
Table 75: The Spectranetics Corporation Pipeline Products & Ongoing Clinical Trials Overview
Table 76: Stellarex Drug Coated Balloon - Below The Knee (BTK) - Product Status
Table 77: Stellarex Drug Coated Balloon - Below The Knee (BTK) - Product Description
Table 78: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Product Status
Table 79: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Product Description
Table 80: The Spectranetics Corporation - Ongoing Clinical Trials Overview
Table 81: Stellarex Drug Coated Balloon - Superficial Femoral Artery - ILLUMENATE First-in-Human (FIH) Study on the Safety and Effectiveness of Covidien’s Advanced Drug-coated Balloon (DCB) Technology
Table 82: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Prospective, Single-arm, Global Multi-center Study to Evaluate Treatment of Obstructive Superficial Femoral Artery and/or Popliteal Lesions with a Novel Paclitaxel-coated Percutaneous Angioplasty Balloon (ILLUMENATE GLOBAL)
Table 83: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Prospective, Single-arm, Multi-center, Pharmacokinetic Study to Evaluate Treatment of Obstructive Superficial Femoral Artery or Popliteal Lesions with a Novel Paclitaxel-coated Percutaneous Angioplasty Balloon
Table 84: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Stellarex Vascular E-Registry
Table 85: Vascular Nanotransfer Technologies Pipeline Products & Ongoing Clinical Trials Overview
Table 86: Mitomycin-Based Drug Coated Balloon - Peripheral - Product Status
Table 87: Mitomycin-Based Drug Coated Balloon - Peripheral - Product Description
Table 88: Paclitaxel-Based Drug Coated Balloon - Peripheral - Product Status
Table 89: Paclitaxel-Based Drug Coated Balloon - Peripheral - Product Description
Table 90: Glossary
1.2 List of Figures
Figure 1: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development
Figure 2: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Territory
Figure 3: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path
Figure 4: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date
Figure 5: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Ongoing Clinical Trials

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report